DAPIPRAZOLE HYDROCHLORIDE Drug Patent Profile

When do Dapiprazole Hydrochloride patents expire, and when can generic versions of Dapiprazole Hydrochloride launch?

Dapiprazole Hydrochloride is a drug marketed by Baradaina Llc and Fera Pharms and is included in two NDAs.

The generic ingredient in DAPIPRAZOLE HYDROCHLORIDE is dapiprazole hydrochloride. There are two drug master file entries for this compound. Additional details are available on the dapiprazole hydrochloride profile page.

Summary for DAPIPRAZOLE HYDROCHLORIDE

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for DAPIPRAZOLE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baradaina Llc	DAPIPRAZOLE HYDROCHLORIDE	dapiprazole hydrochloride	SOLUTION/DROPS;OPHTHALMIC	204902-001	May 30, 2019		DISCN	No	No
Fera Pharms	DAPIPRAZOLE HYDROCHLORIDE	dapiprazole hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019849-001	Dec 31, 1990		DISCN	Yes	No

International Patents for DAPIPRAZOLE HYDROCHLORIDE

See the table below for patents covering DAPIPRAZOLE HYDROCHLORIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	186635
Austria	A292479
Portugal	69502
United Kingdom	2020269	CYCLOALKYLATRIAZOLES AND PROCESS FOR OBTAINING SAME
Yugoslavia	86279
Ireland	47965	CYCLOALKYLTRIAZOLES AND PROCESS FOR OBTAINING SAME

DAPIPRAZOLE HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: February 3, 2026

What is the investment potential of dapiprazole hydrochloride?

Dapiprazole hydrochloride remains an experimental drug with limited commercial approval. Its current clinical applications are primarily in diagnostic procedures and ocular indications, with potential for repurposing in other therapeutic areas. Expect modest near-term revenue driven by niche ophthalmological uses. Long-term investment prospects depend on successful trial outcomes and regulatory approval for expanded indications.

What are the core clinical and regulatory details?

Dapiprazole hydrochloride is a dopamine D2 receptor antagonist historically used to reverse alpha-adrenergic blocker effects during ocular surgeries. Its primary approved use is for chemical iris dilation reversal in ophthalmology. The drug has not received widespread approval for indications outside research or experimental use.

Clinical trials are ongoing or proposed to evaluate efficacy in conditions such as:

• Central nervous system disorders
• Psychiatric indications
• Other ocular applications

No significant approvals for systemic indications have been granted globally.

How does the current patent landscape affect investment?

Patent status varies by jurisdiction. The original patents for dapiprazole expired decades ago, leading to a landscape open to generics. However, newer formulations, delivery methods, or specific uses may be protected via secondary patents, extending commercial exclusivity.

Major considerations:

Patent Status	Details
Original patents expired	Patents filed in the 1980s; expired in late 1990s
Secondary patents	Filed for novel formulations or delivery systems
Patent enforcement	Limited, due to age and global patent expiry

This patent environment suggests low barriers for generic manufacturers but offers opportunities for companies with novel formulations or indications.

What is the competitive landscape?

Dapiprazole's primary competitors are other reversal agents and ocular drugs used in similar contexts. Notable competitors include:

• Phenylephrine: alpha-adrenergic agonist used for pupil dilation
• Tropicamide: short-acting mydriatic
• Pharmacological reversal agents in development targeting similar pathways

Limited direct competition exists in the D2 receptor antagonism space for topical ocular uses.

What are the key markets?

The global ophthalmology market was valued at approximately $35 billion in 2022, with expected compound annual growth rate (CAGR) of 4.2% through 2027. The niche segment where dapiprazole is used is relatively small but stable, emphasizing procedural and diagnostic applications.

Potential expansion into CNS or psychiatric indications could access larger markets, such as:

• Schizophrenia (market size ~$10 billion, 2022)
• Parkinson’s disease (market size ~$11 billion, 2022)

However, these indications require significant clinical validation and regulatory clearance, which adds risk and cost.

What are the commercial and R&D investment considerations?

R&D Costs: Trials for new indications or formulations cost $50-150 million depending on scope, duration, and complexity. Smaller proof-of-concept studies in ocular use cost significantly less, typically under $20 million.

Regulatory Pathways: Regulatory agencies, including FDA and EMA, require robust evidence of safety and efficacy. For repurposing, IND (Investigational New Drug) applications and supplemental NDA (New Drug Application) approvals are necessary, adding timelines of 1-3 years.

Manufacturing: Existing synthesis routes are established but may require adaptation for new formulations. Scaling up production may cost $10-30 million.

Market Access & Reimbursement: Limited reimbursement data exists for niche ocular uses; broader indications could face reimbursement challenges but also provide premium pricing.

Strategic Considerations:

• Focus on niche ocular reversal applications for near-term revenue.
• Invest in clinical trials to validate novel systemic indications.
• Pursue patent protection for formulations to extend market exclusivity.
• Consider partnerships with ophthalmology device companies or CNS research firms.

What are the financial outlooks?

Dapiprazole hydrochloride's revenue potential in niche ocular use is modest, with annual sales possibly reaching $100 million if widely adopted. Risks include delayed approvals, competition, and limited formulary inclusion. Expanding into systemic indications could unlock billion-dollar markets but involves high R&D costs and regulatory risks.

Key financial metrics to monitor:

• R&D expenditure timelines and outcomes
• Patent filings and expirations
• Regulatory approval timelines
• Market penetration rates

What are the risks and mitigation strategies?

Risks:

• Clinical trial failures for new indications
• Regulatory delays or rejections
• Competition from well-established drugs
• Patent challenges on secondary patents

Mitigation:

• Focus on predictive biomarkers for other indications
• Secure patent protections on formulations
• Engage key opinion leaders early
• Conduct thorough market analysis to target high-potential niches

Key Takeaways

• Dapiprazole hydrochloride is an established, low-cost, niche drug primarily used as an ocular reversal agent.
• Investment opportunities are strongest in its current applications with potential for niche market growth.
• Long-term value depends on expanding into CNS or systemic indications, which requires significant investment and validation.
• Patent landscape favors generics but offers opportunities for formulations or indication-specific protections.
• The market size is small in ophthalmology but could scale with successful repurposing efforts into larger therapeutic areas.

FAQs

1. What are the main clinical uses of dapiprazole hydrochloride today?
It is primarily used in ophthalmology to reverse alpha-adrenergic blockades during surgical procedures.

2. What are the prospects for dapiprazole in CNS indications?
They depend on successful clinical trials demonstrating efficacy and safety. No existing approvals currently support these indications.

3. How does patent expiry affect market exclusivity?
Expired patents allow for generic manufacturing, reducing pricing power and profit margins unless secondary patents protect new formulations.

4. What is the typical timeframe to develop a new indication for dapiprazole?
Roughly 3-5 years, including preclinical studies, clinical trials, and regulatory review.

5. Is dapiprazole hydrochloride a high-growth investment?
Currently, it has limited growth potential unless significant new indications or formulations are commercialized successfully.

---

References

1. MarketsandMarkets. Ophthalmology Drugs Market, 2022.
2. FDA. Drug Development and Approval Process, 2023.
3. Patent Databases. Secondary patent landscapes, 2022.
4. GlobalData. CNS Market Reports, 2022.
5. Industry Reports. Ophthalmology procedural market, 2022.